The final, formatted version of the article will be published soon.
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Pediatric Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1466818
This article is part of the Research Topic Pediatric Myeloid Neoplasms: New Insights Into Diagnosis, Prognosis, and Treatment View all 4 articles
Prognostic Factors and Outcomes in Pediatric Acute Myeloid Leukemia: A Comprehensive Bibliometric Analysis of Global Research Trends
Provisionally accepted- 1 Sun Yat-sen Memorial Hospital, Guangzhou, China
- 2 Heyuan People's Hospital, Heyuan, Guangdong, China
Abstract Background Pediatric AML prognosis research has advanced significantly, yet gaps in understanding genetic and molecular interactions persist. Despite improved outcomes, relapse/refractory cases and personalized treatment integration remain critical clinical challenges. Objective To analyze the global research landscape on pediatric AML prognosis, highlight influential components and collaborations, and identify major potential research trends. Methods Publications on pediatric AML prognosis research from 1999 to 2023 were retrieved from the Clarivate Analytics Web of Science Core Collection (WoSCC) database. Bibliometric analysis was conducted using CiteSpace and VOSviewer to identify leading countries, prominent institutions, high-impact journals, key research categories, influential authors, and emerging research topics. Results The bibliometric analysis encompassed 924 publications, with St. Jude Children’s Research Hospital emerging as the most prolific institution. The United States leads globally in terms of countries, institutions, journals, and authors. Todd A. Alonzo ranks highest in publication volume, while U. Creutzig leads in citations. The top research categories were Oncology, Hematology, and Pediatrics. Key research topics included genomics, transcriptomics, epigenomics, targeted therapies, immune therapy, and integrative diagnostic approaches. Conclusion This bibliometric analysis highlights significant advancements in pediatric AML prognosis over the past 25 years, driven by the integration of genetic markers, immunological insights, transcriptomics, and epigenomics, which have collectively transformed risk stratification and treatment strategies. Overcoming challenges, such as discovering new therapeutic targets and enhancing treatment combinations, will depend on global collaboration and advanced technologies to propel the field forward. Keywords Pediatric AML, Prognosis, Bibliometric Analysis, Genetic Markers, immune therapy
Keywords: Pediatric AML, prognosis, bibliometric analysis, Genetic Markers, immune therapy
Received: 26 Jul 2024; Accepted: 27 Dec 2024.
Copyright: © 2024 Rao, Luo, Luo, Xu, Wei, Deng, Li, Wu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mingliang Rao, Sun Yat-sen Memorial Hospital, Guangzhou, China
Wenna Luo, Heyuan People's Hospital, Heyuan, Guangdong, China
Caiju Luo, Sun Yat-sen Memorial Hospital, Guangzhou, China
Tiantian Xu, Sun Yat-sen Memorial Hospital, Guangzhou, China
Ziqian Wei, Sun Yat-sen Memorial Hospital, Guangzhou, China
Haolan Deng, Sun Yat-sen Memorial Hospital, Guangzhou, China
Kejing Li, Sun Yat-sen Memorial Hospital, Guangzhou, China
Baojing Wu, Sun Yat-sen Memorial Hospital, Guangzhou, China
Dunhua Zhou, Sun Yat-sen Memorial Hospital, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.